Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | AGTR1 | P30556 | 4/20 | 0.40 |
| ▸ | AGTR2 | P50052 | 4/20 | 0.40 |
| ▸ | GPR18 | Q14330 | 1/20 | 0.40 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9708605 | 0.90 | ADORA2B (0.42) | AGTR1AGTR2ADORA2AADORA2B | |
| SCHEMBL9708298 | 0.90 | ADORA2B (0.40) | KDM4EHPGDAGTR1AGTR2ADORA2A | |
| SCHEMBL9707625 | 0.89 | KDM4E (0.41) | KDM4EHPGDAGTR1AGTR2ADORA2B | |
| SCHEMBL9707844 | 0.89 | AGTR1 (0.45) | AGTR1AGTR2GPR18 | |
| SCHEMBL9708094 | 0.88 | AGTR1 (0.39) | KDM4EHPGDAGTR1AGTR2 | |
| SCHEMBL9707407 | 0.88 | GPR18 (0.39) | KDM4EHPGDAGTR1AGTR2GPR18 | |
| SCHEMBL9708519 | 0.88 | DCTPP1 (0.42) | KDM4EHPGDAGTR1AGTR2DCTPP1 | |
| SCHEMBL9708425 | 0.88 | AGTR1 (0.46) | AGTR1AGTR2 | |
| SCHEMBL9708252 | 0.88 | ADORA3 (0.42) | KDM4EHPGDAGTR1AGTR2ADORA2B | |
| SCHEMBL9707907 | 0.87 | GPR18 (0.37) | KDM4EHPGDAGTR1AGTR2GPR18 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1992007852-A1 | BIPHENYLALKYL XANTHINE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. (US) | 1992-05-14 | — | — | WO | disclosed |